Drug resistant TB treatment outcomes in Novokuznetsk Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007
Is it possible to achieve treatment success, recommended by WHO in country with high level of multidrug resistant TB? Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001
Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Drug resistant tuberculosis in Belarus Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003
Drug resistant tuberculosis in Odessa, Southern Ukraine: Beijing family strains prevalence and the role of prisons in drug resistant TB transmission Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006
Drug resistance in tuberculosis Source: Eur Respir J 2005; 25: 376-379 Year: 2005
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Drug resistance rates in tuberculosis according to case definitions in a reference hospital of Turkey Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Cohort analysis in country with high level of multidrug resistant TB: how and when? Source: Eur Respir J 2002; 20: Suppl. 38, 402s Year: 2002
Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India? Source: Eur Respir J, 50 (1) 1602182; 10.1183/13993003.02182-2016 Year: 2017
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Outcomes of directly observed treatment for drug resistant tuberculosis Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016